Year |
Citation |
Score |
2018 |
Elewski BE, Kircik LH, Stasko N, De Leon E, Enloe C, Durham T, Maeda-Chubachi T. A Phase 2, Controlled, Dose-Ranging Study of SB208, an Investigational Topical Nitric Oxide-Releasing Drug, for the Treatment of Tinea Pedis. Journal of Drugs in Dermatology : Jdd. 17: 888-893. PMID 30124729 |
0.349 |
|
2018 |
Stasko N, McHale K, Hollenbach SJ, Martin M, Doxey R. Nitric Oxide-Releasing Macromolecule Exhibits Broad-spectrum Anti-Fungal Activity and Utility as a Topical Treatment for Superficial Fungal Infections. Antimicrobial Agents and Chemotherapy. PMID 29760128 DOI: 10.1128/Aac.01026-17 |
0.36 |
|
2018 |
Maeda-Chubachi T, Hollenbach S, Reeve R, León Ed, Reams T, Stasko N. 1306 Topical nitric oxide releasing therapy with SB208 increased fingernail growth Journal of Investigative Dermatology. 138. DOI: 10.1016/J.Jid.2018.03.1323 |
0.406 |
|
2017 |
McHale K, Gil J, Davis S, Hollenbach S, Stasko N. 709 Nitric oxide-releasing topical therapeutic agent for atopic dermatitis Journal of Investigative Dermatology. 137: S122. DOI: 10.1016/J.Jid.2017.02.732 |
0.45 |
|
2017 |
Hollenbach S, McHale K, Martin M, Doxey R, Ross J, Stasko N. 703 Preclinical evidence for nitric oxide-releasing SB414 in a psoriasis animal model Journal of Investigative Dermatology. 137: S121. DOI: 10.1016/J.Jid.2017.02.726 |
0.425 |
|
2016 |
McHale K, Balogh K, Wang H, Hollenbach S, Christensen N, Chow L, Broker T, Stasko N. 536 In vitro and in vivo efficacy of nitric oxide-releasing antiviral therapeutic agents Journal of Investigative Dermatology. 136: S95. DOI: 10.1016/J.Jid.2016.02.574 |
0.38 |
|
2010 |
Johnson TA, Stasko NA, Matthews JL, Cascio WE, Holmuhamedov EL, Johnson CB, Schoenfisch MH. Reduced ischemia/reperfusion injury via glutathione-initiated nitric oxide-releasing dendrimers. Nitric Oxide : Biology and Chemistry / Official Journal of the Nitric Oxide Society. 22: 30-6. PMID 19914388 DOI: 10.1016/J.Niox.2009.11.002 |
0.57 |
|
2008 |
Hetrick EM, Shin JH, Stasko NA, Johnson CB, Wespe DA, Holmuhamedov E, Schoenfisch MH. Bactericidal efficacy of nitric oxide-releasing silica nanoparticles. Acs Nano. 2: 235-46. PMID 19206623 DOI: 10.1021/Nn700191F |
0.54 |
|
2008 |
Geer CB, Stasko NA, Rus IA, Lord ST, Schoenfisch MH. Influence of glutathione and its derivatives on fibrin polymerization. Biomacromolecules. 9: 1876-82. PMID 18570468 DOI: 10.1021/Bm800146J |
0.546 |
|
2008 |
Stasko NA, Fischer TH, Schoenfisch MH. S-nitrosothiol-modified dendrimers as nitric oxide delivery vehicles. Biomacromolecules. 9: 834-41. PMID 18247567 DOI: 10.1021/Bm7011746 |
0.59 |
|
2007 |
Stasko NA, Johnson CB, Schoenfisch MH, Johnson TA, Holmuhamedov EL. Cytotoxicity of polypropylenimine dendrimer conjugates on cultured endothelial cells. Biomacromolecules. 8: 3853-9. PMID 18004811 DOI: 10.1021/Bm7008203 |
0.52 |
|
2007 |
Polizzi MA, Stasko NA, Schoenfisch MH. Water-soluble nitric oxide-releasing gold nanoparticles. Langmuir : the Acs Journal of Surfaces and Colloids. 23: 4938-43. PMID 17375944 DOI: 10.1021/La0633841 |
0.659 |
|
2006 |
Stasko NA, Schoenfisch MH. Dendrimers as a scaffold for nitric oxide release. Journal of the American Chemical Society. 128: 8265-71. PMID 16787091 DOI: 10.1021/Ja060875Z |
0.612 |
|
Low-probability matches (unlikely to be authored by this person) |
2016 |
Baldwin H, Blanco D, McKeever C, Paz N, Vasquez YN, Quiring J, Enloe C, De León E, Stasko N. Results of a Phase 2 Efficacy and Safety Study with SB204, an Investigational Topical Nitric Oxide-releasing Drug for the Treatment of Acne Vulgaris. The Journal of Clinical and Aesthetic Dermatology. 9: 12-8. PMID 27672413 |
0.251 |
|
2018 |
Tyring SK, Rosen T, Berman B, Stasko N, Durham T, Maeda-Chubachi T. A Phase 2 Controlled Study of SB206, a Topical Nitric Oxide-Releasing Drug for Extragenital Wart Treatment. Journal of Drugs in Dermatology : Jdd. 17: 1100-1105. PMID 30365591 |
0.24 |
|
2021 |
Stasko N, Kocher JF, Annas A, Henson I, Seitz TS, Miller JM, Arwood L, Roberts RC, Womble TM, Keller EG, Emerson S, Bergmann M, Sheesley ANY, Strong RJ, Hurst BL, et al. Visible blue light inhibits infection and replication of SARS-CoV-2 at doses that are well-tolerated by human respiratory tissue. Scientific Reports. 11: 20595. PMID 34663881 DOI: 10.1038/s41598-021-99917-2 |
0.148 |
|
2022 |
Kocher J, Arwood L, Roberts RC, Henson I, Annas A, Emerson D, Stasko N, Fulcher ML, Brotton M, Randell SH, Cockrell AS. Visible blue light inactivates SARS-CoV-2 variants and inhibits Delta replication in differentiated human airway epithelia. Biorxiv : the Preprint Server For Biology. PMID 35132416 DOI: 10.1101/2022.01.25.477616 |
0.131 |
|
2022 |
Stockslager MA, Kocher JF, Arwood L, Stasko N, McDonald RA, Tapsak MA, Emerson D. Efficacy and hazards of 425 nm oral cavity light dosing to inactivate SARS-CoV-2. Journal of Dentistry. 123: 104203. PMID 35724941 DOI: 10.1016/j.jdent.2022.104203 |
0.124 |
|
2022 |
Stasko N, Cockrell AS, Kocher JF, Henson I, Emerson D, Wang Y, Smith JR, Henderson NH, Wood H, Bradrick SS, Jones T, Santander J, McNeil JG. A randomized, controlled, feasibility study of RD-X19 in subjects with mild-to-moderate COVID-19 in the outpatient setting. Clinical and Translational Science. PMID 35137532 DOI: 10.1111/cts.13249 |
0.1 |
|
2018 |
Hollenbach S, Stasko N, Nakatsuji T, Gallo R. LB1571 Effects of SB414 cream on S. aureus and tissue cytokines in an atopic dermatitis mouse model Journal of Investigative Dermatology. 138: B18. DOI: 10.1016/j.jid.2018.06.108 |
0.087 |
|
2022 |
Gibson S, Saunders R, Stasko N, Bickerstaff CB, Oakley J, Osterman M, Torres RT, Kish JK, Feinberg BA, Emerson D. Economic and clinical impact of a novel, light-based, at-home antiviral treatment on mild-to-moderate COVID-19. Journal of Medical Economics. 25: 503-514. PMID 35387539 DOI: 10.1080/13696998.2022.2055370 |
0.039 |
|
Hide low-probability matches. |